Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Shares Outstanding (Diluted Average) (2019 - 2025)

Maxcyte (MXCT) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $106.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 1.63% to $106.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $106.3 million, a 1.63% increase, with the full-year FY2024 number at $104.8 million, up 1.53% from a year prior.
  • Shares Outstanding (Diluted Average) was $106.3 million for Q3 2025 at Maxcyte, roughly flat from $106.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $106.3 million in Q3 2025 to a low of $81.0 million in Q1 2021.
  • A 5-year average of $99.7 million and a median of $103.1 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 30.45% in 2021, then rose 1.13% in 2024.
  • Maxcyte's Shares Outstanding (Diluted Average) stood at $90.6 million in 2021, then rose by 12.23% to $101.7 million in 2022, then rose by 1.54% to $103.3 million in 2023, then increased by 1.53% to $104.8 million in 2024, then rose by 1.41% to $106.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Shares Outstanding (Diluted Average) are $106.3 million (Q3 2025), $106.2 million (Q2 2025), and $106.0 million (Q1 2025).